NEORX CORPORATION CHANGE OF CONTROL AGREEMENT (CEO)Change of Control Agreement • February 23rd, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
THIS CHANGE OF CONTROL AGREEMENT (CEO) (this "Agreement"), dated as of February 19, 2004, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the "Company"), and JACK L. BOWMAN (the "Executive").
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTNeorx Corp • February 23rd, 2004 • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this "Agreement"), dated as of February 28, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the "Company"), and Anna Wight (the "Executive").
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTExecutive Severance Agreement • February 23rd, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this "Agreement"), dated as of February 28, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the "Company"), and Linda Findlay (the "Executive").
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENTNeorx Corp • February 23rd, 2004 • In vitro & in vivo diagnostic substances • Washington
This Key Executive Severance Agreement (VP) (this "Agreement"), dated as of May 13, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the "Company"), and KAREN AUDITORE-HARGREAVES (the "Executive").
NEORX CORPORATION CHANGE OF CONTROL AGREEMENTChange of Control Agreement • February 23rd, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances • Washington
This Change of Control Agreement (VP) (this "Agreement"), dated as of May 13, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the "Company"), and KAREN AUDITORE-HARGREAVES (the "Executive").
